Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Mantle-Cell 12Lymphoma, Non-Hodgkin 10Recurrence 9Lymphoma, B-Cell 9Lymphoma 8Dendritic Cell Sarcoma, Interdigitating 3Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Cytokine Release Syndrome 1Ann Arbor Stage II Mantle Cell Lymphoma 1Aggression 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × glofitamab × Clear all
NCT06634589 2026-05-11

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

BeOne Medicines

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡